EA000758B1 - Способ лечения биполярного расстройства - Google Patents

Способ лечения биполярного расстройства Download PDF

Info

Publication number
EA000758B1
EA000758B1 EA199800819A EA199800819A EA000758B1 EA 000758 B1 EA000758 B1 EA 000758B1 EA 199800819 A EA199800819 A EA 199800819A EA 199800819 A EA199800819 A EA 199800819A EA 000758 B1 EA000758 B1 EA 000758B1
Authority
EA
Eurasian Patent Office
Prior art keywords
olanzapine
bipolar disorder
patient
treatment
per day
Prior art date
Application number
EA199800819A
Other languages
English (en)
Russian (ru)
Other versions
EA199800819A1 (ru
Inventor
Чарльз М. мл. Бисли
Гари Д. Толлефсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199800819A1 publication Critical patent/EA199800819A1/ru
Publication of EA000758B1 publication Critical patent/EA000758B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
EA199800819A 1996-03-11 1996-12-04 Способ лечения биполярного расстройства EA000758B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1315996P 1996-03-11 1996-03-11
PCT/US1996/019575 WO1997033577A1 (en) 1996-03-11 1996-12-04 Method for treating bipolar disorder

Publications (2)

Publication Number Publication Date
EA199800819A1 EA199800819A1 (ru) 1999-02-25
EA000758B1 true EA000758B1 (ru) 2000-04-24

Family

ID=21758606

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800819A EA000758B1 (ru) 1996-03-11 1996-12-04 Способ лечения биполярного расстройства

Country Status (15)

Country Link
EP (1) EP0889725A4 (no)
JP (1) JP2000506859A (no)
KR (1) KR19990087713A (no)
CN (1) CN1213966A (no)
AU (1) AU734011B2 (no)
BR (1) BR9612548A (no)
CZ (1) CZ290298A3 (no)
EA (1) EA000758B1 (no)
HU (1) HUP9903679A3 (no)
IL (1) IL126162A0 (no)
NO (1) NO984189L (no)
NZ (1) NZ326031A (no)
PL (1) PL328925A1 (no)
TR (1) TR199801797T2 (no)
WO (1) WO1997033577A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
MY127938A (en) * 1998-05-22 2007-01-31 Lilly Co Eli Combinatin therapy for treatment of partial responders or refractory depression
CZ20004280A3 (cs) * 1998-05-29 2001-09-12 Eli Lilly And Company Lék pro léčbu bipolárních poruch a farmaceutický prostředek
EP1133300B1 (en) 1998-11-23 2005-01-05 Sepracor Inc. Desmethylolanzapine compositions and methods
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
DE69912635T2 (de) * 1998-11-23 2004-05-13 Sepracor Inc., Marlborough Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
HUP9903679A3 (en) 2001-10-29
EP0889725A1 (en) 1999-01-13
CZ290298A3 (cs) 1999-10-13
HUP9903679A2 (hu) 2000-04-28
AU1330797A (en) 1997-10-01
WO1997033577A1 (en) 1997-09-18
NZ326031A (en) 2001-05-25
CN1213966A (zh) 1999-04-14
NO984189D0 (no) 1998-09-11
EP0889725A4 (en) 2000-01-19
AU734011B2 (en) 2001-05-31
BR9612548A (pt) 1999-07-20
KR19990087713A (ko) 1999-12-27
PL328925A1 (en) 1999-03-01
NO984189L (no) 1998-09-11
JP2000506859A (ja) 2000-06-06
TR199801797T2 (xx) 1998-12-21
EA199800819A1 (ru) 1999-02-25
IL126162A0 (en) 1999-05-09

Similar Documents

Publication Publication Date Title
EA000758B1 (ru) Способ лечения биполярного расстройства
US6159963A (en) Method for treating substance abuse
AU709181B2 (en) Method for treating autism
US5744470A (en) Method for treating insomnia
CA2248753C (en) Use of olanzapine for treating excessive aggression
EP1007050B1 (en) Olanzapine for treating substance abuse
EA000793B1 (ru) Способ лечения бессонницы
US6071902A (en) Method for treating excessive aggression
MXPA98007431A (en) Medications to treat the bipo disorder
CA2248905A1 (en) Method for treating bipolar disorder
GB2305859A (en) Treatment of obsessive-compulsive disorder
MXPA98007438A (en) Medications to treat the insom
AU725940C (en) Method for treating substance abuse
GB2305860A (en) Anti-emetic
MXPA98007430A (en) Medications for the treatment of the car

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU